Pancreatic Cancer Market to Progress at a CAGR of 7.3 % by 2032 | DelveInsight

The pancreatic cancer market is anticipated to show positive growth, mainly attributed to the increasing incident cases and also, the launch of upcoming therapies during the forecast period. Moreover, the advances in disease mechanisms have yielded new diagnostic and therapeutic approaches, opening the way to more medicine development. 

LAS VEGAS, Aug. 1, 2022 /PRNewswire/ -- DelveInsight's Pancreatic Cancer Market Insights report includes a comprehensive understanding of current treatment practices, pancreatic cancer emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM (the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), and Japan.

Key Takeaways from the Pancreatic Cancer Market Report

• As per DelveInsight analysis, the pancreatic cancer market size in the 7MM was approximately USD 1,649 million in 2021.
• As per the estimates, the total incident cases of pancreatic cancer were approx 175K in the 7MM in 2021. 
• Leading pancreatic cancer companies such as AstraZeneca, Merck Sharp & Dohme LLC, Bayer, Roche, Celgene, Bristol Myers Squibb, BioLineRx, Alligator Bioscience, Bellicum Pharmaceuticals, OSE Immunotherapeutics, Actuate Therapeutics, FibroGen, NeoImmuneTech, NOXXON Pharma, Silenseed Ltd., Amgen, NGM Biopharmaceuticals, Merus, Mirati Therapeutics, Rexahn Pharmaceuticals, Ocuphire Pharma, Processa Pharmaceuticals, ImmunityBio, Berg, Panbela Therapeutics, GlaxoSmithKline, Eleison Pharmaceuticals, Molecular Templates, Lokon Pharma AB, Cantargia AB, and others are developing novel pancreatic cancer drugs that can be available in the pancreatic cancer market in the upcoming years.
• The pancreatic cancer therapies in the pipeline include Motixafortide, Mitazalimab,  BPX-601, Tedopi (OSE2101), AZD5305,  Elraglusib (9 ING 41),  NT-I7 (Efineptakin Alfa),  Olaptesed pegol (NOX-A12),  siG12D LODER, Sotorasib (LUMAKRAS/AMG 510),  NGM120, Zenocutuzumab (Zeno, MCLA-128),  Adagrasib (MRTX849), RX-3117, Anktiva (N-803), BPM31510 (ubidecarenone), Zejula (niraparib), Glufosfamide, LOAd703 (delolimogene mupadenorepvec), Pamrevlumab, GVAX Pancreatic Tumor Vaccine, and others.
• The pancreatic cancer market is expected to grow due to factors like an increase in the patient pool and the expected launch of novel emerging therapies.

Discover more about therapies set to grab major pancreatic cancer market share @ Pancreatic Cancer Research

Pancreatic Cancer Overview

Pancreatic cancer develops in the tissues of the pancreas, an organ in the abdomen located behind the bottom portion of the stomach. The pancreas produces hormones that assist control blood sugar and release enzymes that promote digestion. Pancreatic cancer is a disorder in which malignant (cancer) cells originate in pancreatic tissues. The pancreas can grow in various ways, including malignant and noncancerous tumors. However, the exact pancreatic cancer causes are unknown. The average life expectancy of pancreatic cancer for individuals who are diagnosed before the tumor develops or spreads is 3 to 3.5 years.

Pancreatic cancer symptoms may include jaundice, dark urine, weight loss, loss of appetite, weariness, and others. The pancreatic cancer diagnosis is difficult as the symptoms are frequently confused with those of other disorders, such as irritable bowel syndrome. Pancreatic cancer treatment options are determined by the degree of cancer. Options may include surgery, chemotherapy, radiation therapy, targeted therapy, or a combination of these.

Learn more about the diseases and pancreatic cancer diet @ Pancreatic Cancer Tests

Pancreatic Cancer Epidemiology Segmentation

As per DelveInsight, there were approx 175K pancreatic cancer incident cases in the 7MM in 2021.

Among the EU5 countries, Germany had the highest incident cases of pancreatic cancer in 2021.

The pancreatic cancer market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Incident Cases of Pancreatic Cancer
• Molecular Alteration-specific Incident Cases of Pancreatic Cancer
• Stage-specific Incident Cases of Pancreatic Cancer

Download the report to understand which factors are driving pancreatic cancer epidemiology trends @ Pancreatic Cancer Epidemiological Insights

Pancreatic Cancer Treatment Market 

Surgical treatment is preferred for patients whose disease has been identified as localized or regional. Aside from surgery, chemotherapy is the most popular pharmaceutical pancreatic cancer treatment option. It is preferred for pancreatic cancer patients in all situations. Gemcitabine-based chemotherapeutic regimens are favored over 5-FU-based and other regimens in first-line therapy due to fewer side effects associated with gemcitabine compared to 5-FU-based treatment choices.

Gemcitabine + nab-paclitaxel can be used as second-line therapy for individuals who meet certain criteria and have had first-line FOLFIRINOX. In the second-line scenario, monotherapy with GEM or 5-FU is possible for patients with a somewhat low-performance status (ECOG 2), those with medical comorbidities, or elderly patients.

Moreover, research and development activities for early detection methods, as well as identifying and developing a potential molecule that can be efficiently used for treating pancreatic cancer patients while imparting the least adverse events, are ongoing in the scientific community. The approval of any upcoming entities currently being evaluated in various clinical phases will significantly alter the treatment landscape for pancreatic cancer patients in the coming years.

To know more about pancreatic cancer treatment options, visit @ Pancreatic Cancer Prevention

Pancreatic Cancer Pipeline Therapies and Key Companies

• Motixafortide (BL-8040): BioLineRx/Merck Sharp & Dohme
• Mitazalimab (ADC-1013): Alligator Bioscience
• BPX-601: Bellicum Pharmaceuticals
• Tedopi (OSE2101): OSE Immunotherapeutics
• AZD5305: Astra Zeneca
• Elraglusib (9 ING 41): Actuate Therapeutics
• Pamrevlumab (FG-3019): FibroGen
• NT-I7 (Efineptakin Alfa): NeoImmuneTech
• Olaptesed pegol (NOX-A12): NOXXON Pharma
• siG12D LODER: Silenseed Ltd
• Sotorasib (LUMAKRAS/AMG 510): Amgen
• NGM120: NGM Biopharmaceuticals
• Zenocutuzumab (Zeno, MCLA-128): Merus
• Adagrasib (MRTX849): Mirati Therapeutics
• RX-3117: Rexahn Pharmaceuticals/Ocuphire Pharma/Processa Pharmaceuticals
• Anktiva (N-803): ImmunityBio
• BPM31510 (ubidecarenone): Berg
• SBP-101: Panbela Therapeutics
• Zejula (niraparib): GlaxoSmithKline/Bristol Myers Squibb
• Glufosfamide: Eleison Pharmaceuticals/Molecular Templates
• LOAd703 (delolimogene mupadenorepvec): Lokon Pharma AB
• CAN04 (Nadunolimab): Cantargia AB
• GVAX Pancreatic Tumor Vaccine: Bristol-Myers Squibb

Learn more about the pancreatic cancer therapies in clinical trials @ New Treatment for Pancreatic Cancer 

Pancreatic Cancer Market Dynamics

As the number of instances of pancreatic cancer rises, so does the pancreatic cancer market size. With the advent of genomic profiling technology and selective molecular targeted medicines, biomarkers have become increasingly significant in the clinical management of pancreatic cancer patients. Moreover, survival in pancreatic cancer patients is constantly improving, indicating that a better understanding of tumor pathobiology will lead to better therapies and outcomes in the pancreatic cancer market. Furthermore, due to a dearth of randomized neoadjuvant trials, research into the use of newer and more aggressive systemic regimens in the neoadjuvant setting to treat PDAC could potentially enhance outcomes in the pancreatic cancer market. Agents targeting the four most prevalent mutations in pancreatic cancer, KRAS, TP53, CDKN2A, and SMAD4, are still in clinical trials, and after the launch, they will change the pancreatic cancer market dynamics.

However, several factors are limiting the growth of the pancreatic cancer market. PDAC is a complicated disease with high intra-tumoral heterogeneity and a thick, desmoplastic stroma that might restrict drug delivery to the tumor. Furthermore, it foreshadows an exceedingly intricate interplay of intercellular signals, making in vitro disease research difficult. Because of the genetic mutation diversity and dense connective tissue that forms the pancreas, PDAC is one of the most chemo-resistant types of cancer.

Moreover, the advent of generics in the pancreatic cancer market, the expiration of patent protection for certain medications, higher healthcare costs, and a sense of nihilism in patients are all major risks to the pancreatic cancer market. Furthermore, drug development in pancreatic cancer is difficult. Pancreatic cancer has the lowest overall success rate of any solid tumor, at around 10%, which is the primary aspect hindering the growth of the pancreatic cancer market.

Scope of the Pancreatic Cancer Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Pancreatic Cancer Companies: AstraZeneca, Merck Sharp & Dohme LLC, Bayer, Roche, Celgene, Bristol Myers Squibb, BioLineRx, Alligator Bioscience, Bellicum Pharmaceuticals, OSE Immunotherapeutics, Actuate Therapeutics, FibroGen, NeoImmuneTech, NOXXON Pharma, Silenseed Ltd., Amgen, NGM Biopharmaceuticals, Merus, Mirati Therapeutics, Rexahn Pharmaceuticals, Ocuphire Pharma, Processa Pharmaceuticals, ImmunityBio, Berg, Panbela Therapeutics, GlaxoSmithKline, Eleison Pharmaceuticals, Molecular Templates, Lokon Pharma AB, Cantargia AB, and others
• Key Pancreatic Cancer Therapies: Motixafortide, Mitazalimab,  BPX-601, Tedopi (OSE2101), AZD5305,  Elraglusib (9 ING 41),  NT-I7 (Efineptakin Alfa),  Olaptesed pegol (NOX-A12),  siG12D LODER, Sotorasib (LUMAKRAS/AMG 510),  NGM120, Zenocutuzumab (Zeno, MCLA-128),  Adagrasib (MRTX849), RX-3117, Anktiva (N-803), BPM31510 (ubidecarenone), Zejula (niraparib), Glufosfamide, LOAd703 (delolimogene mupadenorepvec), GVAX Pancreatic Tumor Vaccine, and others
• Therapeutic Assessment: Pancreatic Cancer current marketed and emerging therapies
• Pancreatic Cancer Market Dynamics:  Pancreatic Cancer market drivers and barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, Pancreatic Cancer Market Access and Reimbursement

Discover more about pancreatic cancer drugs in development @ Pancreatic Cancer Clinical Trials

Table of Contents

Get in touch with our Business executive  @ Healthcare Due Diligence Services 

Related Reports

Pancreatic Cancer Epidemiology

Pancreatic Cancer Epidemiology Forecast to 2032 report delivers an in-depth understanding of the disease, historical, and forecasted Pancreatic Cancer epidemiology in the 7MM.

Pancreatic Cancer Pipeline

Pancreatic Cancer Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key pancreatic cancer companies, including FibroGen, NeoImmuneTech, NOXXON Pharma, Silenseed Ltd., Amgen, NGM Biopharmaceuticals, among others.

Advanced Pancreatic Cancer Market

Advanced Pancreatic Cancer Market Insight, Epidemiology, and Market Forecast, 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key advanced pancreatic cancer companies, including AstraZeneca, Merck Sharp & Dohme LLC, Bayer, Roche, among others.

Advanced Pancreatic Cancer Pipeline

Advanced Pancreatic Cancer Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key advanced pancreatic cancer companies, including FibroGen, NeoImmuneTech, NOXXON Pharma, Silenseed Ltd., Amgen, NGM Biopharmaceuticals, among others.

Metastatic Pancreatic Cancer Market

Metastatic Pancreatic Cancer Market Insight, Epidemiology, and Market Forecast, 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key metastatic pancreatic cancer companies, including Takeda Oncology, Salspera, Eli Lilly and Company, among others.

Metastatic Pancreatic Cancer Pipeline

Metastatic Pancreatic Cancer Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key metastatic pancreatic cancer companies, including Takeda Oncology, Salspera, Eli Lilly and Company, among others.

Other Trending Reports

Persistent Depressive Disorder Market | Gene Therapy for Ocular Rare Disease Market | Congestive Heart Failure Market | CRISPR Therapies Pipeline | Desmoplastic Small Round Cell Tumors Market | India Healthcare Outlook Report | Psychosis Market | Dental Lasers Market | Primary Immune Deficiency Market I Dyslipidemia Market | Lateral Epicondylitis Disease Market | Castration-Resistant Prostate Cancer Market | Metrorrhagia Market | Global Messenger RNA-based Vaccines and Therapeutics Market | Negative Pressure Wound Therapy Systems Market | US Healthcare Outlook Report | Mucinous Cystic Neoplasms Market | Hot Flashes Market | Varicose Veins - Market | Hemostats Market | Injectable Drug Delivery Devices Market | Breast Pumps Market | Physiotherapy Equipment Market | Trastuzumab Biosimilars Insight | Deep Brain Stimulation Devices Market | Retinoblastoma Market | Venous Stenosis Market | Tumor Ablation Market | Substance Abuse Market | Insulin Glargine Biosimilar Insight | Interspinous Spacers Market | Anti-hypertension Market

Related Healthcare Blogs 

Upcoming Oncology Drugs

Oncology Market Outlook

Future of Oncology Market

Related Cases Studies

Competitive Intelligence

Market Assessment

Product Assessment

Epidemiology Assessment

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect with us on LinkedIn|Facebook|Twitter

Contact Us :
Shruti Thakur  
[email protected] 
+1(919)321-6187 
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg 

SOURCE DelveInsight Business Research, LLP